Enveric Biosciences (ENVB) Stock Price, News & Analysis

Company Overview

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Key Stats

• Today's Range: $0.31 to $0.33
• 50-Day Range: $0.31 to $0.55
• 52-Week Range: $0.30 to $2.92
• Volume: 86,415 shs
• Average Volume: 1.65 million shs
• Market Capitalization: $3.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Buy

Enveric Biosciences Stock Analysis - MarketRank™

Enveric Biosciences scored higher than 52% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Enveric Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Enveric Biosciences has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Enveric Biosciences are expected to grow in the coming year, from ($2.08) to ($1.41) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Enveric Biosciences is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Enveric Biosciences is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Enveric Biosciences has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.24% of the float of Enveric Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Enveric Biosciences has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Enveric Biosciences has recently decreased by 57.57%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Enveric Biosciences does not currently pay a dividend.

Dividend Growth

Enveric Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.24% of the float of Enveric Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Enveric Biosciences has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Enveric Biosciences has recently decreased by 57.57%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

2 people have searched for ENVB on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Enveric Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Enveric Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.20% of the stock of Enveric Biosciences is held by insiders.

Percentage Held by Institutions

Only 13.82% of the stock of Enveric Biosciences is held by institutions.

ENVB Stock Analysis - Frequently Asked Questions

How have ENVB shares performed this year?

Enveric Biosciences' stock was trading at $1.30 on January 1st, 2024. Since then, ENVB shares have decreased by 76.2% and is now trading at $0.31.
View the best growth stocks for 2024 here.

How were Enveric Biosciences' earnings last quarter?

Enveric Biosciences, Inc. (NASDAQ:ENVB) released its quarterly earnings results on Monday, August, 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.30.

When did Enveric Biosciences' stock split?

Enveric Biosciences's stock reverse split on the morning of Friday, July 15th 2022. The 1-50 reverse split was announced on Friday, July 15th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of Enveric Biosciences?

Shares of ENVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Enveric Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Enveric Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), CrowdStrike (CRWD), Broadcom (AVGO), ServiceNow (NOW) and Adobe (ADBE).

Company Calendar

• Last Earnings: 8/12/2024
• Today: 12/26/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ENVB
• CUSIP: N/A
• CIK: 890821
• Web: jaypharma.co
• Phone: (239) 302-1707
• Fax: 732-243-9254
• Employees: 7
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $10.00
• High Stock Price Target: $10.00
• Low Stock Price Target: $10.00
• Potential Upside/Downside: +3,125.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.56)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-17,290,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -221.54%
• Return on Assets: -164.32%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.17
• Quick Ratio: 5.17

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.71 per share
• Price / Book: 0.44

Miscellaneous

• Outstanding Shares: 10,170,000
• Free Float: 9,826,000
• Market Cap: $3.15 million
• Optionable: Not Optionable
• Beta: 0.68